세계의 제네릭 종양학 의약품 시장 : 산업 분석, 규모, 점유율, 성장, 동향 예측(2024-2033년)

Persistence Market Research has recently released a comprehensive report on the global Generic Oncology Drugs Market, providing an in-depth analysis of key market dynamics, including drivers, trends, opportunities, and challenges. This report offers detailed insights into the market's structure and growth potential.

Key Insights:

• Generic Oncology Drugs Market Size (2024E): USD 27.69 Bn
• Projected Market Value (2033F): USD 48.9 Bn
• Global Market Growth Rate (CAGR 2024 to 2033): 6.5%

Generic Oncology Drugs Market - Report Scope:

Generic oncology drugs are becoming increasingly critical in the healthcare sector due to their affordability and effectiveness in treating various cancers. These drugs provide an essential alternative to branded cancer treatments, making them accessible to a larger population, especially in developing regions. The rising incidence of cancer, coupled with the need for cost-effective treatments, is a significant driver of the market. Generic oncology drugs cover a broad spectrum of cancer treatments, including chemotherapy, immunotherapy, and targeted therapies, contributing to the market's growth.

Market Growth Drivers:

Several key factors are driving the growth of the global generic oncology drugs market. The increasing prevalence of cancer worldwide and the rising demand for affordable treatment options are crucial drivers. Governments and healthcare organizations are focusing on reducing the financial burden on patients, which is further boosting the demand for generic oncology drugs. Additionally, patent expirations of key branded cancer drugs are creating opportunities for the development and introduction of generic alternatives. The growing awareness and acceptance of generic medicines as effective and safe alternatives to branded drugs are also contributing to market expansion.

Market Restraints:

Despite its significant growth potential, the generic oncology drugs market faces challenges. One of the primary hurdles is the complexity and high cost associated with the development and approval of generic oncology drugs, which can slow down market entry for new players. Furthermore, strict regulatory requirements and intellectual property laws can limit the availability of generics in certain regions. Additionally, concerns related to the bioequivalence and efficacy of generic oncology drugs compared to their branded counterparts can impact market growth.

Market Opportunities:

The generic oncology drugs market presents substantial opportunities, particularly in emerging markets where access to affordable cancer treatment is a priority. The increasing focus on healthcare infrastructure development and government initiatives to promote generic drugs in these regions is expected to drive market growth. Moreover, advancements in drug manufacturing processes and the exploration of biosimilar drugs as a viable alternative for expensive cancer treatments offer new avenues for market expansion. Strategic collaborations between generic drug manufacturers and healthcare providers will further enhance the availability and adoption of these drugs.

Key Questions Answered in the Report:

• What are the primary factors driving the global generic oncology drugs market?
• Which cancer types are seeing the highest adoption of generic oncology drugs, and in which regions?
• How are regulatory frameworks and patent expirations influencing the competitive landscape of this market?
• Who are the leading players in the generic oncology drugs market, and what strategies are they using to maintain their market positions?
• What are the emerging trends and future prospects in the global generic oncology drugs market?

Competitive Intelligence and Business Strategy:

Leading players in the global generic oncology drugs market, such as Teva Pharmaceuticals, Mylan N.V., and Fresenius Kabi, are focusing on innovation, product expansion, and strategic partnerships to strengthen their positions. These companies are heavily investing in research and development to improve drug formulations, expand their oncology portfolios, and ensure compliance with stringent regulatory standards. Collaborations with hospitals and healthcare systems are essential for market penetration, particularly in high-growth regions. As the demand for affordable cancer treatment continues to rise, companies in this space are prioritizing quality, efficacy, and availability to ensure long-term success in the generic oncology drugs market.

Key Companies Profiled:

• Bausch Health Companies Inc.
• Novartis
• Pfizer
• GSK
• Celgene
• Teva Pharmaceuticals
• Merck & Company
• Aurobindo Pharma
• Hikma Pharmaceuticals
• Mylan
• NATCO Pharma

Key Segments Covered in Generic Oncology Drugs Industry Research

Molecule:

• Large Molecule
• Small Molecule

Route of Administration:

• Oral
• Parenteral

Distribution Channel:

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacies
• Managed Care Institutions

Region:

• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East & Africa

Table of Contents

1. Executive Summary

• 1.1. Global Market Outlook
• 1.2. Demand Side Trends
• 1.3. Supply Side Trends
• 1.4. Analysis and Recommendations

2. Market Overview

• 2.1. Market Coverage / Taxonomy
• 2.2. Market Definition / Scope / Limitations
• 2.3. Inclusions and Exclusions

3. Key Market Trends

• 3.1. Key Trends Impacting the Market
• 3.2. Product Innovation / Development Trends

4. Key Success Factors

• 4.1. Product Adoption Analysis
• 4.2. Usage Analysis - Key Statistics
• 4.3. Value Chain Analysis
• 4.4. Recent Product Approvals/Launches
• 4.5. Key Regulations - By Region
• 4.6. Product USP Analysis
• 4.7. Pipeline Assessment

5. Market Background

• 5.1. Macroeconomic Factors
  • 5.1.1. Global GDP Growth Outlook
  • 5.1.2. Global Healthcare Expenditure Overview
  • 5.1.3. Global Generic Drugs Market Outlook
• 5.2. Forecast Factors - Relevance & Impact
  • 5.2.1. Rising Prevalence of Cancer
  • 5.2.2. Increasing Generic Product Approvals
  • 5.2.3. Increasing Cases of Cancer Patients
  • 5.2.4. Mergers and Acquisitions
  • 5.2.5. Regulatory Policies
  • 5.2.6. Recent Product Approvals
  • 5.2.7. Product Pipeline
  • 5.2.8. Advertisements and Endorsements
• 5.3. Market Dynamics
  • 5.3.1. Drivers
  • 5.3.2. Restraints
  • 5.3.3. Opportunity Analysis

6. COVID-19 Crisis Analysis

• 6.1. COVID-19 and Impact Analysis
  • 6.1.1. By Molecule Type
  • 6.1.2. By Route of Administration
  • 6.1.3. By Distribution Channel
  • 6.1.4. By Region
• 6.2. 2024 Market Scenario

7. Global Generic Oncology Drugs Market Demand (in Value US$ Bn) Analysis 2019-2023 and Forecast, 2024-2033

• 7.1. Historical Market Value (US$ Bn) Analysis, 2019-2023
• 7.2. Current and Future Market Value (US$ Bn) Projections, 2024-2033
  • 7.2.1. Y-o-Y Growth Trend Analysis
  • 7.2.2. Absolute $ Opportunity Analysis

8. Global Generic Oncology Drugs Market Analysis 2019-2023 and Forecast 2024-2033, By Molecule Type

• 8.1. Introduction / Key Findings
• 8.2. Historical Market Size (US$ Bn) Analysis, by Molecule Type, 2019-2023
• 8.3. Current and Future Market Size (US$ Bn) Analysis and Forecast, by Molecule Type, 2024-2033
  • 8.3.1. Large Molecule
  • 8.3.2. Small Molecule
• 8.4. Market Attractiveness Analysis, by Molecule Type

9. Global Generic Oncology Drugs Market Analysis 2019-2023 and Forecast 2024-2033, By Route of Administration

• 9.1. Introduction / Key Findings
• 9.2. Historical Market Size (US$ Bn) Analysis, By Route of Administration, 2019-2023
• 9.3. Current and Future Market Size (US$ Bn) Analysis and Forecast, by Route of Administration, 2024-2033
  • 9.3.1. Oral
  • 9.3.2. Parenteral
• 9.4. Market Attractiveness Analysis, by Route of Administration

10. Global Generic Oncology Drugs Market Analysis 2019-2023 and Forecast 2024-2033, By Distribution Channel

• 10.1. Introduction / Key Findings
• 10.2. Historical Market Size (US$ Bn) Analysis, By Distribution Channel, 2019-2023
• 10.3. Current and Future Market Size (US$ Bn) Analysis and Forecast, by Distribution Channel, 2024-2033
  • 10.3.1. Hospital Pharmacy
  • 10.3.2. Retail Pharmacy
  • 10.3.3. Online Pharmacies
  • 10.3.4. Managed Care Institutions
• 10.4. Market Attractiveness Analysis, by Distribution Channel

11. Global Generic Oncology Drugs Market Analysis 2019-2023 and Forecast 2024-2033, By Region

• 11.1. Introduction
• 11.2. Historical Market Size (US$ Bn) Analysis, by Region, 2019-2023
• 11.3. Current and Future Market Value (US$ Bn) Analysis and Forecast, By Region, 2024-2033
  • 11.3.1. North America
  • 11.3.2. Latin America
  • 11.3.3. Europe
  • 11.3.4. East Asia
  • 11.3.5. South Asia
  • 11.3.6. Oceania
  • 11.3.7. Middle East and Africa (MEA)
• 11.4. Market Attractiveness Analysis, by Region

12. North America Generic Oncology Drugs Market Analysis 2019-2023 and Forecast 2024-2033

• 12.1. Introduction
• 12.2. Historical Market Size (US$ Bn) Analysis, by Market Taxonomy, 2019-2023
• 12.3. Current and Future Market Value (US$ Bn) Analysis and Forecast, by Market Taxonomy, 2024-2033
  • 12.3.1. By Country
    • 12.3.1.1. U.S.
    • 12.3.1.2. Canada
  • 12.3.2. By Molecule Type
  • 12.3.3. By Route of Administration
  • 12.3.4. By Distribution Channel
• 12.4. Market Attractiveness Analysis
  • 12.4.1. By Country
  • 12.4.2. By Molecule Type
  • 12.4.3. By Route of Administration
  • 12.4.4. By Distribution Channel
• 12.5. Market Trends
• 12.6. Key Market Participants - Intensity Mapping
• 12.7. Drivers and Restraints - Impact Analysis
• 12.8. Country Level Analysis & Forecast
  • 12.8.1. U.S. Generic Oncology Drugs Market Analysis
    • 12.8.1.1. Introduction
    • 12.8.1.2. Market Analysis and Forecast, by Market Taxonomy
      • 12.8.1.2.1. By Molecule Type
      • 12.8.1.2.2. By Route of Administration
      • 12.8.1.2.3. By Distribution Channel
  • 12.8.2. Canada Generic Oncology Drugs Market Analysis
    • 12.8.2.1. Introduction
    • 12.8.2.2. Market Analysis and Forecast, by Market Taxonomy
      • 12.8.2.2.1. By Molecule Type
      • 12.8.2.2.2. By Route of Administration
      • 12.8.2.2.3. By Distribution Channel

13. Latin America Generic Oncology Drugs Market Analysis 2019-2023 and Forecast 2024-2033

• 13.1. Introduction
• 13.2. Historical Market Size (US$ Bn) Analysis, by Market Taxonomy, 2019-2023
• 13.3. Current and Future Market Value (US$ Bn) Analysis and Forecast, by Market Taxonomy, 2024-2033
  • 13.3.1. By Country
    • 13.3.1.1. Mexico
    • 13.3.1.2. Brazil
    • 13.3.1.3. Argentina
    • 13.3.1.4. Rest of Latin America
  • 13.3.2. By Molecule Type
  • 13.3.3. By Route of Administration
  • 13.3.4. By Distribution Channel
• 13.4. Market Attractiveness Analysis
  • 13.4.1. By Country
  • 13.4.2. By Molecule Type
  • 13.4.3. By Route of Administration
  • 13.4.4. By Distribution Channel
• 13.5. Market Trends
• 13.6. Key Market Participants - Intensity Mapping
• 13.7. Drivers and Restraints - Impact Analysis
• 13.8. Country Level Analysis & Forecast
  • 13.8.1. Mexico Generic Oncology Drugs Market Analysis
    • 13.8.1.1. Introduction
    • 13.8.1.2. Market Analysis and Forecast, by Market Taxonomy
      • 13.8.1.2.1. By Molecule Type
      • 13.8.1.2.2. By Route of Administration
      • 13.8.1.2.3. By Distribution Channel
  • 13.8.2. Brazil Generic Oncology Drugs Market Analysis
    • 13.8.2.1. Introduction
    • 13.8.2.2. Market Analysis and Forecast, by Market Taxonomy
      • 13.8.2.2.1. By Molecule Type
      • 13.8.2.2.2. By Route of Administration
      • 13.8.2.2.3. By Distribution Channel
  • 13.8.3. Argentina Generic Oncology Drugs Market Analysis
    • 13.8.3.1. Introduction
    • 13.8.3.2. Market Analysis and Forecast, by Market Taxonomy
      • 13.8.3.2.1. By Molecule Type
      • 13.8.3.2.2. By Route of Administration
      • 13.8.3.2.3. By Distribution Channel

14. Europe Generic Oncology Drugs Market Analysis 2019-2023 and Forecast 2024-2033

• 14.1. Introduction
• 14.2. Historical Market Size (US$ Bn) Analysis, by Market Taxonomy, 2019-2023
• 14.3. Current and Future Market Value (US$ Bn) Analysis and Forecast, by Market Taxonomy, 2024-2033
  • 14.3.1. By Country
    • 14.3.1.1. Germany
    • 14.3.1.2. Italy
    • 14.3.1.3. France
    • 14.3.1.4. U.K.
    • 14.3.1.5. Spain
    • 14.3.1.6. BENELUX
    • 14.3.1.7. Russia
    • 14.3.1.8. Rest of Europe
  • 14.3.2. By Molecule Type
  • 14.3.3. By Route of Administration
  • 14.3.4. By Distribution Channel
• 14.4. Market Attractiveness Analysis
  • 14.4.1. By Country
  • 14.4.2. By Molecule Type
  • 14.4.3. By Route of Administration
  • 14.4.4. By Distribution Channel
• 14.5. Market Trends
• 14.6. Key Market Participants - Intensity Mapping
• 14.7. Drivers and Restraints - Impact Analysis
• 14.8. Country Level Analysis & Forecast
  • 14.8.1. Germany Generic Oncology Drugs Market Analysis
    • 14.8.1.1. Introduction
    • 14.8.1.2. Market Analysis and Forecast, by Market Taxonomy
      • 14.8.1.2.1. By Molecule Type
      • 14.8.1.2.2. By Route of Administration
      • 14.8.1.2.3. By Distribution Channel
  • 14.8.2. Italy Generic Oncology Drugs Market Analysis
    • 14.8.2.1. Introduction
    • 14.8.2.2. Market Analysis and Forecast, by Market Taxonomy
      • 14.8.2.2.1. By Molecule Type
      • 14.8.2.2.2. By Route of Administration
      • 14.8.2.2.3. By Distribution Channel
  • 14.8.3. France Generic Oncology Drugs Market Analysis
    • 14.8.3.1. Introduction
    • 14.8.3.2. Market Analysis and Forecast, by Market Taxonomy
      • 14.8.3.2.1. By Molecule Type
      • 14.8.3.2.2. By Route of Administration
      • 14.8.3.2.3. By Distribution Channel
  • 14.8.4. U.K. Generic Oncology Drugs Market Analysis
    • 14.8.4.1. Introduction
    • 14.8.4.2. Market Analysis and Forecast, by Market Taxonomy
      • 14.8.4.2.1. By Molecule Type
      • 14.8.4.2.2. By Route of Administration
      • 14.8.4.2.3. By Distribution Channel
  • 14.8.5. Spain Generic Oncology Drugs Market Analysis
    • 14.8.5.1. Introduction
    • 14.8.5.2. Market Analysis and Forecast, by Market Taxonomy
      • 14.8.5.2.1. By Molecule Type
      • 14.8.5.2.2. By Route of Administration
      • 14.8.5.2.3. By Distribution Channel
  • 14.8.6. BENELUX Generic Oncology Drugs Market Analysis
    • 14.8.6.1. Introduction
    • 14.8.6.2. Market Analysis and Forecast, by Market Taxonomy
      • 14.8.6.2.1. By Molecule Type
      • 14.8.6.2.2. By Route of Administration
      • 14.8.6.2.3. By Distribution Channel
  • 14.8.7. Russia Generic Oncology Drugs Market Analysis
    • 14.8.7.1. Introduction
    • 14.8.7.2. Market Analysis and Forecast, by Market Taxonomy
      • 14.8.7.2.1. By Molecule Type
      • 14.8.7.2.2. By Route of Administration
      • 14.8.7.2.3. By Distribution Channel

15. East Asia Generic Oncology Drugs Market Analysis 2019-2023 and Forecast 2024-2033

• 15.1. Introduction
• 15.2. Historical Market Size (US$ Bn) Analysis, by Market Taxonomy, 2019-2023
• 15.3. Current and Future Market Value (US$ Bn) Analysis and Forecast, by Market Taxonomy, 2024-2033
  • 15.3.1. By Country
    • 15.3.1.1. China
    • 15.3.1.2. Japan
    • 15.3.1.3. South Korea
  • 15.3.2. By Molecule Type
  • 15.3.3. By Route of Administration
  • 15.3.4. By Distribution Channel
• 15.4. Market Attractiveness Analysis
  • 15.4.1. By Molecule Type
  • 15.4.2. By Route of Administration
  • 15.4.3. By Distribution Channel
• 15.5. Market Trends
• 15.6. Key Market Participants - Intensity Mapping
• 15.7. Drivers and Restraints - Impact Analysis
• 15.8. Country Level Analysis & Forecast
  • 15.8.1. China Generic Oncology Drugs Market Analysis
    • 15.8.1.1. Introduction
    • 15.8.1.2. Market Analysis and Forecast, by Market Taxonomy
      • 15.8.1.2.1. By Molecule Type
      • 15.8.1.2.2. By Route of Administration
      • 15.8.1.2.3. By Distribution Channel
  • 15.8.2. Japan Generic Oncology Drugs Market Analysis
    • 15.8.2.1. Introduction
    • 15.8.2.2. Market Analysis and Forecast, by Market Taxonomy
      • 15.8.2.2.1. By Molecule Type
      • 15.8.2.2.2. By Route of Administration
      • 15.8.2.2.3. By Distribution Channel
  • 15.8.3. South Korea Generic Oncology Drugs Market Analysis
    • 15.8.3.1. Introduction
    • 15.8.3.2. Market Analysis and Forecast, by Market Taxonomy
      • 15.8.3.2.1. By Molecule Type
      • 15.8.3.2.2. By Route of Administration
      • 15.8.3.2.3. By Distribution Channel

16. South Asia Generic Oncology Drugs Market Analysis 2019-2023 and Forecast 2024-2033

• 16.1. Introduction
• 16.2. Historical Market Size (US$ Bn) Analysis, by Market Taxonomy, 2019-2023
• 16.3. Current and Future Market Value (US$ Bn) Analysis and Forecast, by Market Taxonomy, 2024-2033
  • 16.3.1. By Country
    • 16.3.1.1. India
    • 16.3.1.2. Indonesia
    • 16.3.1.3. Malaysia
    • 16.3.1.4. Thailand
    • 16.3.1.5. Rest of South Asia
  • 16.3.2. By Molecule Type
  • 16.3.3. By Route of Administration
  • 16.3.4. By Distribution Channel
• 16.4. Market Attractiveness Analysis
  • 16.4.1. By Country
  • 16.4.2. By Molecule Type
  • 16.4.3. By Route of Administration
  • 16.4.4. By Distribution Channel
• 16.5. Market Trends
• 16.6. Key Market Participants - Intensity Mapping
• 16.7. Drivers and Restraints - Impact Analysis
• 16.8. Country Level Analysis & Forecast
  • 16.8.1. India Generic Oncology Drugs Market Analysis
    • 16.8.1.1. Introduction
    • 16.8.1.2. Market Analysis and Forecast, by Market Taxonomy
      • 16.8.1.2.1. By Molecule Type
      • 16.8.1.2.2. By Route of Administration
      • 16.8.1.2.3. By Distribution Channel
  • 16.8.2. Indonesia Generic Oncology Drugs Market Analysis
    • 16.8.2.1. Introduction
    • 16.8.2.2. Market Analysis and Forecast, by Market Taxonomy
      • 16.8.2.2.1. By Molecule Type
      • 16.8.2.2.2. By Route of Administration
      • 16.8.2.2.3. By Distribution Channel
  • 16.8.3. Malaysia Generic Oncology Drugs Market Analysis
    • 16.8.3.1. Introduction
    • 16.8.3.2. Market Analysis and Forecast, by Market Taxonomy
      • 16.8.3.2.1. By Molecule Type
      • 16.8.3.2.2. By Route of Administration
      • 16.8.3.2.3. By Distribution Channel
  • 16.8.4. Thailand Generic Oncology Drugs Market Analysis
    • 16.8.4.1. Introduction
    • 16.8.4.2. Market Analysis and Forecast, by Market Taxonomy
      • 16.8.4.2.1. By Molecule Type
      • 16.8.4.2.2. By Route of Administration
      • 16.8.4.2.3. By Distribution Channel

17. Oceania Generic Oncology Drugs Market 2019-2023 and Forecast 2024-2033

• 17.1. Introduction
• 17.2. Historical Market Size (US$ Bn) Analysis, by Market Taxonomy, 2019-2023
• 17.3. Current and Future Market Value (US$ Bn) Analysis and Forecast, by Market Taxonomy, 2024-2033
  • 17.3.1. By Country
    • 17.3.1.1. Australia
    • 17.3.1.2. New Zealand
  • 17.3.2. By Molecule Type
  • 17.3.3. By Route of Administration
  • 17.3.4. By Distribution Channel
• 17.4. Market Attractiveness Analysis
  • 17.4.1. By Country
  • 17.4.2. By Molecule Type
  • 17.4.3. By Route of Administration
  • 17.4.4. By Distribution Channel
• 17.5. Key Market Participants - Intensity Mapping
• 17.6. Key Market Participants - Intensity Mapping
• 17.7. Drivers and Restraints - Impact Analysis
• 17.8. Country Level Analysis & Forecast
  • 17.8.1. Australia Generic Oncology Drugs Market Analysis
    • 17.8.1.1. Introduction
    • 17.8.1.2. Market Analysis and Forecast, by Market Taxonomy
      • 17.8.1.2.1. By Molecule Type
      • 17.8.1.2.2. By Route of Administration
      • 17.8.1.2.3. By Distribution Channel
  • 17.8.2. New Zealand Generic Oncology Drugs Market Analysis
    • 17.8.2.1. Introduction
    • 17.8.2.2. Market Analysis and Forecast, by Market Taxonomy
      • 17.8.2.2.1. By Molecule Type
      • 17.8.2.2.2. By Route of Administration
      • 17.8.2.2.3. By Distribution Channel

18. Middle East and Africa (MEA) Generic Oncology Drugs Market Analysis 2019-2023 and Forecast 2024-2033

• 18.1. Introduction
• 18.2. Historical Market Size (US$ Bn) Analysis, by Market Taxonomy, 2019-2023
• 18.3. Current and Future Market Value (US$ Bn) Analysis and Forecast, by Market Taxonomy, 2024-2033
  • 18.3.1. By Country
    • 18.3.1.1. GCC Countries
    • 18.3.1.2. Turkey
    • 18.3.1.3. South Africa
    • 18.3.1.4. North Africa
    • 18.3.1.5. Rest of Middle East and Africa
  • 18.3.2. By Molecule Type
  • 18.3.3. By Route of Administration
  • 18.3.4. By Distribution Channel
• 18.4. Market Attractiveness Analysis
  • 18.4.1. By Country
  • 18.4.2. By Molecule Type
  • 18.4.3. By Route of Administration
  • 18.4.4. By Distribution Channel
• 18.5. Market Trends
• 18.6. Key Market Participants - Intensity Mapping
• 18.7. Drivers and Restraints - Impact Analysis
• 18.8. Country Level Analysis & Forecast
  • 18.8.1. GCC Countries Generic Oncology Drugs Market Analysis
    • 18.8.1.1. Introduction
    • 18.8.1.2. Market Analysis and Forecast, by Market Taxonomy
      • 18.8.1.2.1. By Molecule Type
      • 18.8.1.2.2. By Route of Administration
      • 18.8.1.2.3. By Distribution Channel
  • 18.8.2. Turkey Generic Oncology Drugs Market Analysis
    • 18.8.2.1. Introduction
    • 18.8.2.2. Market Analysis and Forecast, by Market Taxonomy
      • 18.8.2.2.1. By Molecule Type
      • 18.8.2.2.2. By Route of Administration
      • 18.8.2.2.3. By Distribution Channel
  • 18.8.3. South Africa Generic Oncology Drugs Market Analysis
    • 18.8.3.1. Introduction
    • 18.8.3.2. Market Analysis and Forecast, by Market Taxonomy
      • 18.8.3.2.1. By Molecule Type
      • 18.8.3.2.2. By Route of Administration
      • 18.8.3.2.3. By Distribution Channel
  • 18.8.4. North Africa Generic Oncology Drugs Market Analysis
    • 18.8.4.1. Introduction
    • 18.8.4.2. Market Analysis and Forecast, by Market Taxonomy
      • 18.8.4.2.1. By Molecule Type
      • 18.8.4.2.2. By Route of Administration
      • 18.8.4.2.3. By Distribution Channel

19. Market Structure Analysis

• 19.1. Market Analysis, by Tier of Companies
• 19.2. Market Share Analysis of Top Players
• 19.3. Market Concentration
• 19.4. Market Presence Analysis

20. Competition Analysis

• 20.1. Competition Dashboard
• 20.2. Competition Deep Dive
  • 20.2.1. Bausch Health Companies Inc.
    • 20.2.1.1. Overview
    • 20.2.1.2. Product Portfolio
    • 20.2.1.3. Sales Footprint
    • 20.2.1.4. Key Financials
    • 20.2.1.5. SWOT Analysis
    • 20.2.1.6. Strategy Overview
      • 20.2.1.6.1. Marketing Strategy
      • 20.2.1.6.2. Product Strategy
      • 20.2.1.6.3. Channel Strategy
  • 20.2.2. Novartis
    • 20.2.2.1. Overview
    • 20.2.2.2. Product Portfolio
    • 20.2.2.3. Sales Footprint
    • 20.2.2.4. Key Financials
    • 20.2.2.5. SWOT Analysis
    • 20.2.2.6. Strategy Overview
      • 20.2.2.6.1. Marketing Strategy
      • 20.2.2.6.2. Product Strategy
      • 20.2.2.6.3. Channel Strategy
  • 20.2.3. Pfizer
    • 20.2.3.1. Overview
    • 20.2.3.2. Product Portfolio
    • 20.2.3.3. Sales Footprint
    • 20.2.3.4. Key Financials
    • 20.2.3.5. SWOT Analysis
    • 20.2.3.6. Strategy Overview
      • 20.2.3.6.1. Marketing Strategy
      • 20.2.3.6.2. Product Strategy
      • 20.2.3.6.3. Channel Strategy
  • 20.2.4. GSK
    • 20.2.4.1. Overview
    • 20.2.4.2. Product Portfolio
    • 20.2.4.3. Sales Footprint
    • 20.2.4.4. Key Financials
    • 20.2.4.5. SWOT Analysis
    • 20.2.4.6. Strategy Overview
      • 20.2.4.6.1. Marketing Strategy
      • 20.2.4.6.2. Product Strategy
      • 20.2.4.6.3. Channel Strategy
  • 20.2.5. Celgene
    • 20.2.5.1. Overview
    • 20.2.5.2. Product Portfolio
    • 20.2.5.3. Sales Footprint
    • 20.2.5.4. Key Financials
    • 20.2.5.5. SWOT Analysis
    • 20.2.5.6. Strategy Overview
      • 20.2.5.6.1. Marketing Strategy
      • 20.2.5.6.2. Product Strategy
      • 20.2.5.6.3. Channel Strategy
  • 20.2.6. Teva Pharmaceuticals
    • 20.2.6.1. Overview
    • 20.2.6.2. Product Portfolio
    • 20.2.6.3. Sales Footprint
    • 20.2.6.4. Key Financials
    • 20.2.6.5. SWOT Analysis
    • 20.2.6.6. Strategy Overview
      • 20.2.6.6.1. Marketing Strategy
      • 20.2.6.6.2. Product Strategy
      • 20.2.6.6.3. Channel Strategy
  • 20.2.7. Merck & Company
    • 20.2.7.1. Overview
    • 20.2.7.2. Product Portfolio
    • 20.2.7.3. Sales Footprint
    • 20.2.7.4. Key Financials
    • 20.2.7.5. SWOT Analysis
    • 20.2.7.6. Strategy Overview
      • 20.2.7.6.1. Marketing Strategy
      • 20.2.7.6.2. Product Strategy
      • 20.2.7.6.3. Channel Strategy
  • 20.2.8. Aurobindo Pharma
    • 20.2.8.1. Overview
    • 20.2.8.2. Product Portfolio
    • 20.2.8.3. Sales Footprint
    • 20.2.8.4. Key Financials
    • 20.2.8.5. SWOT Analysis
    • 20.2.8.6. Strategy Overview
      • 20.2.8.6.1. Marketing Strategy
      • 20.2.8.6.2. Product Strategy
      • 20.2.8.6.3. Channel Strategy
  • 20.2.9. Hikma Pharmaceuticals
    • 20.2.9.1. Overview
    • 20.2.9.2. Product Portfolio
    • 20.2.9.3. Sales Footprint
    • 20.2.9.4. Key Financials
    • 20.2.9.5. SWOT Analysis
    • 20.2.9.6. Strategy Overview
      • 20.2.9.6.1. Marketing Strategy
      • 20.2.9.6.2. Product Strategy
      • 20.2.9.6.3. Channel Strategy
  • 20.2.10. Mylan
    • 20.2.10.1. Overview
    • 20.2.10.2. Product Portfolio
    • 20.2.10.3. Sales Footprint
    • 20.2.10.4. Key Financials
    • 20.2.10.5. SWOT Analysis
    • 20.2.10.6. Strategy Overview
      • 20.2.10.6.1. Marketing Strategy
      • 20.2.10.6.2. Product Strategy
      • 20.2.10.6.3. Channel Strategy
  • 20.2.11. NATCO Pharma
    • 20.2.11.1. Overview
    • 20.2.11.2. Product Portfolio
    • 20.2.11.3. Sales Footprint
    • 20.2.11.4. Key Financials
    • 20.2.11.5. SWOT Analysis
    • 20.2.11.6. Strategy Overview
      • 20.2.11.6.1. Marketing Strategy
      • 20.2.11.6.2. Product Strategy
      • 20.2.11.6.3. Channel Strategy

21. Assumptions and Acronyms Used

22. Research Methodology